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Summary. Background: There are limited data assessing bronchodilator responsiveness
(BDR) in infants and toddlers with recurrent wheezing, and factors associated with a positive
response. Objectives: In a multicenter study of children  36 months old, we assessed the
prevalence of and factors associated with BDR among infants/toddlers with recurrent episodes
of wheezing. Methods: Forced expiratory ﬂows and volumes using the raised-volume rapid
thoracic compression method were measured in 76 infants/toddlers [mean (SD) age 16.8 (7.6)
months] with recurrent wheezing before and after administration of albuterol. Prior history of
hospitalization or emergency department treatment for wheezing, use of inhaled or systemic
corticosteroids, physician treatment of eczema, environmental tobacco smoke exposure, and
family history of asthma or allergic rhinitis were ascertained. Results: Using the published
upper limit of normal for post bronchodilator change (FEV0.5  13% and/or FEF25–75  24%)
in healthy infants, 24% (n ¼ 18) of children in our study exhibited BDR. The BDR response
was not associated with any clinical factor other than body size. Dichotomizing subjects into
responders (deﬁned by published limits of normal) or by quartile to identify children with the
greatest change from baseline (4th quartile vs. other) did not identify any other factor associat-
ed with BDR. Conclusions: Approximately one quarter of infants/toddlers with recurrent wheez-
ing exhibited BDR at their clinical baseline. However, BDR in wheezy infants/toddlers was not
associated with established clinical asthma risk factors. Pediatr Pulmonol. 2012; 47:421–
428.  2011 Wiley Periodicals, Inc.
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INTRODUCTION
Recurrent wheezing affects 20–30% of infants and
toddlers, yet resolves in at least 50% of these children
by school age.1 Infants and toddlers with recurrent
wheezing are a heterogeneous group. The majority of
wheezy infants and toddlers do not have asthma, but
rather may wheeze for a variety of anatomic and/or
pathophysiologic reasons, including small airway cali-
ber, tracheomalacia, dysphagia, post-viral airway in-
ﬂammation, and injury, or alternations in the maturation
of the immune system such as reduced IFN-g produc-
tion.2,3 Clinicians generally cannot distinguish young
children with transient wheezing from those with early
persistent asthma. Therefore, predictors of asthma in
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wheezy infants and toddlers could lead to major
improvements in the management of these children, po-
tentially reducing preventable healthcare utilization for
thousands of young children and preventing under- or
over-treatment with corticosteroids. In school age chil-
dren, airﬂow obstruction that is at least partially revers-
ible is a hallmark of asthma.4 International expert panel
asthma treatment guidelines4,5 recommend assessment
of reversibility of airﬂow obstruction following admin-
istration of a bronchodilator during spirometry as a key
method to assist with the diagnosis of asthma in chil-
dren over age 5 years. However, among infants and tod-
dlers it is not known whether short-term reversibility of
airﬂow obstruction in response to treatment with
a bronchodilator is correlated with or predictive of
asthma.
Although infants and toddlers are not capable of
independently performing spirometry, the raised-volume
rapid thoracoabdominal compression (RVRTC) tech-
nique can be used to measure forced expiratory ﬂows
and volumes in children  3 years of age under seda-
tion with chloral hydrate. When comparing different in-
fant lung function parameters, RVRTC parameters were
found to be the least variable and thus most likely to
identify a change following administration of a bron-
chodilator.6 During the RVRTC maneuver an infant’s
lungs are inﬂated to near total lung capacity followed
by a forced expiration.7–9 The RVRTC technique allows
generation of ﬂow-volume curves that are similar to
adult-type ﬂow-volume curves. RVRTC forced expirato-
ry ﬂows and volumes have been used to assess infants
with bronchiolitis and recurrent wheezing,10,11 and
reference values from healthy infants are published.12
Although published data describing forced expiratory
volumes and ﬂows following administration of albuterol
in healthy children exist,13 there is a paucity of data
regarding the prevalence of bronchodilator responsive-
ness (BDR) among infants and toddlers with recurrent
wheezing.14 Furthermore, studies in this population
exploring factors associated with BDR, as well as the
predictive value of BDR for asthma later in childhood,
are lacking.
The objectives of this study were to assess the preva-
lence of BDR and factors associated with BDR among
infants and toddlers with recurrent episodes of wheez-
ing. To accomplish these aims, we analyzed forced ex-
piratory ﬂows and volumes obtained at three study sites
in the United States and Canada using the RVRTC tech-
nique in a convenience sample of children <36 months
of age with a history of recurrent episodes of physician-
diagnosed and treated wheezing. We then investigated
associations between clinical factors and changes in
lung function following administration of albuterol. We
hypothesized that BDR would be associated with well
established epidemiologic risk factors of asthma, specif-
ically personal history of eczema and family history of
asthma or atopy.
MATERIALS AND METHODS
Subjects
Data collected from children 4–36 months of age
with 3 prior episodes of physician-diagnosed wheez-
ing treated with bronchodilators or corticosteroids who
were studied at three academic children’s hospitals
were included in this study (Seattle Children’s Hospital,
Seattle, WA; Hospital for Sick Children, University of
Toronto, Toronto, Ontario Canada; and C.S. Mott Child-
ren’s Hospital, University of Michigan, Ann Arbor,
MI). Subjects born <36 weeks gestation or with con-
genital heart disease, dysphagia, severe gastroesophage-
al reﬂux, oxygen saturation 90% on room air, an
active seizure disorder, or upper airway obstruction
were excluded. Subjects did not receive systemic ste-
roids for at least 3 weeks prior to lung function meas-
urements. Subjects at the Seattle and Michigan sites did
not receive inhaled corticosteroids within 3 weeks of
lung function testing, whereas at the Toronto site all
subjects were receiving inhaled corticosteroids at the
time of testing. Written consent was obtained from
parents of subjects. The study was approved by the
Institutional Review Boards of each institution.
Study Visits
Study visits occurred at each child’s baseline state of
health, and a minimum of 2 weeks following resolution
of an upper or lower respiratory infection, or acute
exacerbation of wheezing. Bronchodilators were held
for at least 8 hr prior to lung function measurements.
A detailed medical history was obtained by a study
investigator, including ascertainment of prior history of
hospitalization or emergency department treatment for
wheezing, use of inhaled or systemic corticosteroids,
physician treatment of eczema, environmental tobacco
smoke exposure, ﬁrst-degree relative history of asthma
or allergic rhinitis, and ethnicity. Length and weight
were measured with a calibrated stadiometer and digital
scale at the time of infant lung function testing.
ABBREVIATIONS:
FEV0.5 forced expiratory volume in 0.5 sec
FEF25–75 forced expiratory ﬂow 25–75% of expiration
FEF75 forced expiratory ﬂow at 75% of expiration
RVRTC raised volume rapid thoracoabdominal compression
NHLBI National Heart Lung Blood Institute
ATS American Thoracic Society
ERS European Respiratory Society
FENO fraction of exhaled nitric oxide
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Lung Function Measurements
Forced expiratory volumes and ﬂows (FVC, FEV0.5,
FEF25–75, and FEF75) were measured using the RVRTC
technique according to ATS/ERS guidelines for raised
volume forced expirations in infants15 via the nSpire1
Infant Pulmonary Lab (IPL). Measurement of forced
expiratory ﬂows and volumes were repeated 10 min
after administration of albuterol.13 Two puffs of albute-
rol were administered using a metered dose inhaler
with a spacer. Each puff of albuterol was followed by
an inﬂation of the lungs to 25 cm H2O. Heart rate was
continuously monitored throughout the study. Adequate
systemic delivery was assumed when a 10% increase in
heart rate was achieved. Repeat doses of two puffs were
given if a 10% rise in heart rate was not achieved by
2 min after the previous dose, up to a maximum of
8 puffs. The mean dose of albuterol administered to
subjects was four puffs. Lung function outcomes are
reported as the single best pre- and post albuterol
maneuvers with the highest sum of FVC and FEF25–75.
All curves used for analysis had FVC measurements
within 10% of the highest FVC. Lung function param-
eters were analyzed both as raw values and as z-scores
calculated from published normative data.12
Statistical Analysis
Data were pooled from the three centers; outliers
were investigated and excluded if values were not bio-
logically plausible (e.g., change in FEV0.5 > 200%).
Summary statistics were performed by center, and for
the whole group. Baseline comparisons between groups
were done using an ANOVA and Chi squared test.
Generalized estimating equations (GEE), adjusting for
clustering by centers, were used to analyze the associa-
tion between changes in lung function post bronchodila-
tor and potential predictors. Logistic regression was
applied for the following dichotomous outcome varia-
bles: (1) bronchodilator response deﬁned as FEV0.5 
13% and/or FEF25–75  24%13 and (2) highest quartile
for relative change in FEV0.5, FEF25–75, or FEF75. The
predictor variables considered were sex, age, height-for-
age z-score, weight-for-age z-score, hospital admis-
sions, emergency room visits, environmental tobacco
exposure, prior treatment for eczema, family history of
asthma and family history of allergy. Height-for-age
and weight-for-age z-scores were derived using the
2006 WHO Growth Charts.16 All statistical analysis
was done using STATA (StataCorp. 2001. Statistical
Software: Release 7.0. College Station, TX: Stata
Corporation).
RESULTS
Seventy-six infants from the three centers had accept-
able pre- and post-bronchodilator results. At the Seattle
center, 44/47 enrolled subjects completed acceptable
infant lung function testing, of which 36 subjects
completed acceptable post-bronchodilator lung function
testing. At the Toronto site 32/40 subjects completed
lung function testing, and 25 completed acceptable
post-bronchodilator results. At the Michigan site 15/15
enrolled subjects completed lung function testing with
acceptable post-bronchodilator results. Table 1 summa-
rizes the study population. There were a greater
TABLE 1—Summary of Participant Characteristics
Seattle (n ¼ 36) Michigan (n ¼ 15) Toronto (n ¼ 25) Combined (n ¼ 76) P-value
Sex; n (%) male 25 (69.4) 10 (66.7) 19 (76.0) 54 (71.1) 0.836
Age (months); mean (SD) 17.8 (7.2) 10.8 (3.7) 18.9 (8.3) 16.8 (7.6) 0.0024
Ethnicity; n (%) Caucasian 27 (75.0) 13 (86.7) 17 (68.0) 57 (75.0) 0.520
z-score height; mean (SD) 0.12 (1.1) 0.67 (1.4) 0.40 (1.0) 0.32 (1.1) 0.2758
z-score weight; mean (SD)) 0.61 (1.1) 0.20 (1.2) 0.90 (4.7) 0.62 (2.8) 0.7347
z-score FVC; mean (SD) 0.22 (1.3) 0.41 (1.7) 0.13 (1.4) 0.15 (1.4) 0.5253
z-score FEV0.5; mean (SD) 0.77 (1.2) 0.23 (1.6) 0.48 (1.6) 0.57 (1.4) 0.3734
z-score FEF25–75; mean (SD) 0.91 (1.4) 0.33 (1.4) 0.76 (1.8) 0.75 (1.6) 0.0140
z-score FEF75; mean (SD) 1.0 (1.4) 0.24 (1.4) 0.97 (1.6) 0.84 (1.5) 0.2246
Previous hospitalization; n (%) 14 (38.9) 5 (33.3) 18 (72.0) 37 (48.7) 0.007
Previous ED visit; n (%) 27 (75.0) 11 (73.3) 25 (100) 63 (82.9) 0.029
Current ICS use 0 (0) 0 (0) 25 (100) 25 (32.8) <0.001
History of ICS use; n (%) 6 (17.0) 5(33.3) 25 (100) 29 (38.2) <0.001
History of systemic steroid use; n (%) 28 (78.0) 6 (40.0) 19 (76.0) 53(69.7) <0.001
Household exposure to smoke n (%) 8 (22.2) 5 (33.3) 12 (48.0) 25 (32.9) 0.082
Eczema treatment; n (%) 12 (33.3) 3 (20.0) 2 (8.0) 17 (23.3) 0.042
Family history of asthma; n (%) 19 (52.8) 3 (20.0) 12 (48.0) 45 (59.2) 0.000
Family history of allergy; n (%) 28 (77.8) 11 (73.3) 14 (56.0) 53 (69.7) 0.141
ED, emergency department; ICS, inhaled corticosteroid.
In Toronto, history of asthma and allergy are for parental history only, whereas in Michigan and Seattle all ﬁrst-degree relatives are included.P-values obtained from ANOVA analysis for continuous outcomes and chi squared analysis for categorical outcomes.
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proportion of male infants in all three sites, and 75% of
the study population was Caucasian. The majority of
infants were <18 months at the time of testing (median
16 months, range 4.5–36). On average the children in-
cluded in the study were shorter-for-age and heavier-
for-age than the international reference population16
and had reduced lung function outcomes compared
to a North American reference population12. Prior to
enrolment most children in the study had been treated
with bronchodilators and/or inhaled steroids and more
than half had been treated with at least one course of
systemic corticosteroids. The rate of previous hospital-
izations and emergency room visits was greater at
the Toronto site than at the Seattle and Michigan sites.
The combined prevalence of a positive family history
of asthma or allergy was high and differed between the
centers. Other than FEF25–75 z-score, which was highest
in Michigan with the youngest infants, baseline lung
function did not differ between the centers.
Figure 1 presents the average relative change from
baseline for each of the lung function outcomes. For
FVC the median relative change from baseline follow-
ing administration of albuterol was 1.4% (range 12.0;
30.2); For FEV0.5, the median relative change after
albuterol was 2.4% (range 19.8; 36.8); whereas the
observed change was much greater and more variable
for the two ﬂow outcomes, 10.9% (range 49.6; 110.0)
for FEF75, and 6.1% (range 36.3; 100.9) for FEF25–75.
Using the published upper limit of normal (ULN)
for post-bronchodilator change (FEV0.5  13% and/or
FEF25–75  24%)13, 24% (n ¼ 18) of infants had a
post-bronchodilator change greater than that observed
in healthy subjects. Using the same cut-off for FEF75
instead of FEF25–75, the percentage of children who were
classiﬁed as responders increased to 34% (n ¼ 26).
Only 16% (n ¼ 12) of infants had a post-BDR increase
in FEV0.5 of >12%. The median relative change from
baseline in the ‘‘responders’’ was 14.9% (IQR 6.7–
22.4) for FEV0.5, 0.34% (IQR-3.0; 6.1) for FVC, 35.6%
(IQR 28.3; 52.8) for FEF25–75 and 50.5% (IQR 34.3;
63.3) for FEF75. Stratifying the results by center, using
the published ULN for post-bronchodilator, 17% of
children were classiﬁed as ‘‘responders’’ in Seattle,
40% in Michigan and 21% in Toronto.
Subsequently, we assessed which factors were asso-
ciated with the greatest change in lung function para-
meters following administration of a bronchodilator.
Table 2 summarizes the results from a multi-variable
regression model, taking into account the differences
between centers. The magnitude of change was less
for females, however, this gender difference was not
statistically signiﬁcant. The change in FEF25–75 was
lower in older children and in infants who were taller-
for-age (higher height-for-age z-scores) (Fig. 2). How-
ever, the relationship with age was no longer evident
after taking into account the non-linear relationship
in age with lung function. There was no association
between baseline lung function and height-for-age,
thus these results cannot be explained by regression to
the mean. Furthermore, a sensitivity analysis excluding
a potential outlier conﬁrmed these ﬁndings. Similarly,
dichotomizing the outcomes into responders as deﬁned
by published limits of normal13 and by quartile to iden-
tify those children with the greatest change from base-
line (4th quartile vs. other) did not identify any factors
that were statistically predictive of greater BDR. For
all of the multi-variable models, the variability between
centers was greater than that variability within centers.
DISCUSSION
In a multi-center study of infants and toddlers with
recurrent physician-diagnosed episodes of wheezing,
we found that 24% of children exhibited a response to
albuterol more than two standard deviations greater
than that observed in previous published data assessing
BDR in healthy infants.13 For forced expiratory ﬂows,
the only factor associated with increased BDR amongst
wheezy infants and toddlers was lower z-scores for
height. Aside from body size, we did not ﬁnd any other
factors associated with BDR among young children
with recurrent wheezing, including the well established
asthma risk factors of family history of asthma, family
history of allergy, and personal history of eczema. Fur-
thermore, prior hospitalization or emergency depart-
ment visits for wheezing, were not associated with
BDR in children with known wheezing disorders.
One of our aims was to estimate the prevalence of
BDR in wheezy infants and toddlers utilizing infant
lung function testing. This is the largest study published
Fig. 1. Relative change in lung function from baseline follow-
ing administration of albuterol. FEV0.5: forced expiratory vol-
ume in 0.5 sec; FEF25–75: forced expiratory ﬂow 25–75% of
expiration; FEF75: forced expiratory ﬂow at 75% of expiration.
424 Debley et al.
Pediatric Pulmonology
to date assessing BDR in infants and toddlers with re-
current wheezing. Hayden et al.11 studied 27 wheezy
infants and 5 controls, of which 20 infants received a
bronchodilator and 7 received placebo, and found that
none of the infants had a bronchodilator response
despite a 10% rise in heart-rate following administra-
tion of albuterol indicating adequate delivery. This pop-
ulation was similar to ours in that infants were
tested when asymptomatic. A second study by Saito
et al.14 studied 19 children under age 3 years with
recurrent wheezing who had failed empiric anti-asthma
and/or anti-reﬂux therapy and were scheduled to under-
go bronchoscopy, 17 of which completed pre- and post-
albuterol infant lung function testing. They reported
BDR in 18% of their subjects using a deﬁnition of
a >13% change in FEV0.5 and/or >24% change in
FEF25–75 following albuterol. The prevalence of BDR
reported by Saito et al. was slightly lower than what we
observed. However, 95% of the children studied by
Saito et al. had failed anti-asthma therapies prior to en-
rolment, potentially limiting the generalizability of their
ﬁnding to the larger population of infants and toddlers
with recurrent wheezing. In contrast, the characteristics
and severity of the subjects in our study are more repre-
sentative of infants and toddlers with recurrent wheez-
ing managed by most pediatric caregivers.
BDR in school age children and adults is considered
a key feature of asthma, and international asthma
management guidelines recommend assessment of lung
function after administration of a bronchodilator as
an important evaluation to assist in the diagnosis of
asthma.4,5 Among school age children with asthma, the
prevalence of BDR has been reported between 30 and
60%.17–19 BDR has been found to be associated with
poor asthma control and worse clinical outcomes in
school age children with asthma.19,20 The presence
of BDR in older patients with asthma has also been
reported to be a good predictor of responsiveness to
treatment with inhaled corticosteroids.21–23 Given the
association between BDR and asthma in older children
and adults, BDR in infants and toddlers with recurrent
wheezing might help separate transient wheezers from
children who will go on to develop chronic asthma as
well as assist in decision making regarding long term
use of inhaled corticosteroids in infants and toddlers
with recurrent wheezing. Parental history of asthma and
personal history of eczema are two well established risk
factors for asthma in young children that serve as the
major criteria in the Asthma Predictive Index proposed
by Castro-Rodriquez24 and recommended by asthma
management guidelines to guide decision making re-
garding the initiation of inhaled corticosteroids in
young children with recurrent wheezing.4 We hypothe-
sized that these asthma risk factors would be associated
with BDR. However, not only did we ﬁnd no relation-
ship between BDR and known asthma risk factors,
TABLE 2—Summary of Multi-Variable Regression, Adjusted for Clustering by Center
Relative change following
albuterol; (post-pre)/pre FVC slope (95% CI) FEV0.5 slope (95% CI) FEF75 slope (95% CI) FEF25–75 slope (95% CI)
Sex (females) 2.68 (6.36; 1.00) 4.67 (9.67; 0.34) 14.07 (28.83; 0.69) 1.77 (13.13; 9.59)
Age (months) 0.12 (0.11; 0.34) 0.08 (0.38; 0.23) 0.29 (1.19; 0.62) 0.73 (1.40; 0.05)
z-score height 0.93 (2.43; 0.57) 1.84 (3.88; 0.19) 6.31 (12.28; 0.33) 5.47 (9.99; 0.95)
z-score weight 0.25 (0.84; 0.34) 0.68 (0.13; 1.49) 0.33 (2.76; 2.10) 0.54 (1.31; 2.39)
More than 1 hospital admission 1.30 (2.13; 4.73) 1.66 (3.04; 6.36) 0.95 (13.34; 15.25) 8.50 (2.31; 19.30)
More than 2 ED visit 0.21 (2.45; 2.02) 1.44 (1.62; 4.50) 0.39 (8.82; 9.60) 2.65 (4.40; 9.71)
Household smoke exposure 1.85 (5.43; 1.73) 1.25 (3.68; 6.19) 3.59 (11.22; 18.41) 1.41 (9.78; 12.60)
Previous treatment for eczema 0.12 (4.37; 4.13) 2.04 (7.83; 3.76) 1.06 (18.67; 16.55) 7.62 (20.83; 5.60)
Family history of asthma 3.14 (0.20; 6.47) 1.09 (3.58; 5.77) 2.67 (11.16; 16.51) 4.74 (5.79; 15.29)
Family history of allergy 1.06 (4.73; 2.61) 3.71 (8.69; 1.27) 11.25 (26.11; 3.62) 7.06 (18.31; 4.20)
ED, emergency department; FEV0.5, forced expiratory volume in 0.5 sec; FEF25–75, forced expiratory ﬂow 25–75% of expiration; FEF75,
forced expiratory ﬂow at 75% of expiration.
Bold values indicate P-values <0.05.
Fig. 2. Percentage change from baseline in FEF25–75 follow-
ing administration of albuterol against height for-age z-score.
The change in FEF25–75 was less in infants who were taller
for age (greater height-for-age z-scores).
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we also found that despite a high prevalence of inhaled
steroid use (100%) in Toronto at the time of testing,
there was no difference in the prevalence of BDR or in
baseline lung function when compared to Seattle where
none of the infants were on inhaled steroids at the time
of testing, a ﬁnding in contrast to studies in older chil-
dren and adults demonstrating that inhaled steroids at-
tenuate bronchial hyperresponsiveness.25 This is
consistent with the observations of Saglani et al.26 who
reported that bronchial biopsy specimens from infants
with recurrent wheeze and evidence of BDR lacked
evidence of reticular basement membrane thickening
or eosinophilic airway inﬂammation characteristic of
asthma in older children and adults, suggesting that
BDR in wheezy infants is not pathognomonic of future
asthma and thus may not predict responsiveness to
inhaled steroids.
Interestingly, the only factor that was related to BDR
was a lower height for age z-score. These results
are seemingly in contrast to work in infants with acute
bronchiolitis where age did not seem to predict the
magnitude of the bronchodilator response.27 However,
in our study, we also found that the response with age
was non-linear and the effect was not seen with age but
with height z-score. Of note, Modl et al.27 also found
that BDR had no relationship with known asthma risk
factors. Our ﬁndings raise several concerns regarding
the clinical signiﬁcance of BDR among infants and tod-
dlers with recurrent wheezing. First, if BDR in this pop-
ulation is not associated other established asthma risk
factors, namely eczema and family history of asthma
and allergy, it calls into question the utility of BDR
assessment during infant pulmonary function testing in
predicting future asthma. This is consistent with recent-
ly reported longitudinal data from one of our centers
(Seattle) demonstrating that BDR in wheezing infants
and toddlers is not a strong predictor of subsequent
respiratory exacerbations or changes in lung function
through 3 years of age; and in fact, tests of airway in-
ﬂammation such as single breath exhaled nitric oxide
(SB-FENO) seem to have greater predictive value.28,29
Second, the lack of an association between BDR and
asthma risk factors suggests that the presence of BDR
alone in a wheezy infant or toddler is insufﬁcient
evidence to guide clinical decision making regarding
initiation of an inhaled corticosteroid medication as a
long-term asthma controller.
At the present time, the clinical utility of BDR in the
assessment of wheezing infants is unclear. This is in
part due to the lack of sufﬁcient longitudinal data to
demonstrate the outcome of these infants by school
age. It is known that a signiﬁcant proportion of infants
and toddlers with recurrent wheezing will be asymp-
tomatic with normal lung function at school age.30 On-
going new birth cohorts such as the Canadian Healthy
Infant Longitudinal Development study (CHILD) will
study the pattern of bronchodilator responses in infant
lung function and correlate them with outcomes that
are clinical and physiologic in later life as well as
epidemiologic risk factors24 and other promising bio-
markers (e.g., FENO). These types of longitudinal stud-
ies are needed to fully understand the role of BDR in
infancy.
Airway reactivity in response to a challenge with
methacholine or histamine is not synonymous with
BDR, and we did not assess airway reactivity in our
study population. In a cohort of infants with atopic der-
matitis (mean enrollment age of 10.7 months) Tepper
et al. recently reported that airway reactivity to metha-
choline was not a risk factor for subsequent wheezing
over a 1-year period, although they did ﬁnd that wheez-
ing during follow-up was associated with airway
reactivity measured at the 1-year follow-up visit.31 In
an Australian birth cohort followed from early infancy
through school age Palmer et al.32 reported that reactiv-
ity to histamine at 1 month of age, as measured by a
40% decrease in the maximal ﬂow at functional residual
capacity, was associated with a physician diagnosis
of asthma and decreased lung function at age 6 years.
However, the relationship between airway reactivity
and BDR among infants and toddlers with recurrent
wheezing has not been well elucidated.
There are several limitations inherent in our study
design. First, our study did not include a healthy control
group, but rather compared bronchodilator responses
in wheezy infants to those reported in a previously
published study conducted in healthy infants wherein
BDR cut-offs were assessed among 28 infants treated
with albuterol and 13 subjects that received an inhaled
placebo.13 However, given that our aims were to assess
the prevalence of BDR among wheezy infants, and
associations between BDR and asthma risk factors, this
limitation had little impact on our analyses. Second,
prenatal maternal smoking history, a factor associated
with decreased lung function among children,33–36 was
not assessed in all of our study centers. Third, because
our study population was a convenience sample with
common inclusion and exclusion criteria, potential for
selection bias was a limitation. For example, subjects
enrolled in Seattle and Michigan completed lung func-
tion testing a minimum of 3 weeks after discontinuation
of any inhaled or systemic corticosteroids, whereas
all subjects enrolled in Toronto were studied while
receiving maintenance inhaled steroids, albeit during an
asymptomatic period while not receiving systemic ste-
roids. In addition to corticosteroid use, between-center
differences existed with regards to age, eczema, emer-
gency department treatment, hospitalization, and family
history of asthma. However, we adjusted for center
in our GEE model when analyzing the association
426 Debley et al.
Pediatric Pulmonology
between lung function changes post-bronchodilator and
potential predictors, and included all of the variables
that differed between centers in our logistic regression
models. Finally, the asthma risk factors we assessed in
this cross-sectional analysis do not conﬁrm or exclude
future asthma. Longitudinal analyses of this and other
cohorts of infants and toddlers with recurrent wheezing
followed into the school age years and beyond will
be required to deﬁnitively determine whether BDR
in children less than age 3 years is associated with or
predictive of clinical asthma later in childhood.
In summary, in the ﬁrst multicenter study of infants
and toddlers with recurrent wheezing to rigorously
assess BDR we estimate that approximately one quarter
of infants exhibit an improvement in forced expiratory
ﬂows in response to albuterol. Infant lung function test-
ing utilizing the RVRTC method is technically chal-
lenging as well as time and labor intensive, limiting the
feasibility of conducting such a study with a sufﬁcient
number of subjects at a single center. Our multicenter
approach utilizing the same lung function testing equip-
ment and standardized operating procedures is a signiﬁ-
cant strength of this study. Interestingly, only height
z-score was associated with BDR among infants and
toddlers with recurrent wheezing. In contrast, well-
established asthma risk factors of family history of asth-
ma, family history of allergy, and personal history of
eczema had no relationship with BDR. Although a lon-
gitudinal study will be required to deﬁnitively answer
the question of whether BDR can predict asthma among
wheezy infants, it is likely that identiﬁcation of other
biomarkers will be required to accurately diagnose asth-
ma and guide the use of long-term asthma controller
medications in this important pediatric population.
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